Insmed Inc (INSM)vsRein Therapeutics Inc (RNTX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RNTX
Rein Therapeutics Inc
$1.30
+6.56%
HEALTHCARE · Cap: $31.28M
Smart Verdict
WallStSmart Research — data-driven comparison
RNTX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
RNTX
Avoid19
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RNTX
RNTX has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RNTX
The primary concerns for RNTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RNTX is a value play — different risk/reward profiles.
RNTX carries more volatility with a beta of 1.54 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
RNTX generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Rein Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rein Therapeutics Inc (RNTX) is an innovative biopharmaceutical company committed to advancing next-generation therapies aimed at neurodegenerative disorders. Leveraging its proprietary technology platform that integrates advanced neuroscience with drug development, the company is poised to address critical unmet medical needs through a robust and diversified pipeline. Supported by a team of seasoned industry experts, Rein Therapeutics is strategically located in a rapidly evolving therapeutic landscape, presenting a compelling opportunity for institutional investors seeking to engage with pioneering healthcare innovations.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?